vs
Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $16.9M, roughly 1.6× FVCBankcorp, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs 4.6%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $3.9M). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs 21.8%).
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
FVCB vs SMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.9M | $27.5M |
| Net Profit | — | $-1.6M |
| Gross Margin | — | 93.2% |
| Operating Margin | 43.7% | 23.5% |
| Net Margin | — | -5.9% |
| Revenue YoY | 4377.5% | 4.6% |
| Net Profit YoY | — | 5.3% |
| EPS (diluted) | $0.31 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.9M | $27.5M | ||
| Q3 25 | $416.0K | $26.3M | ||
| Q2 25 | $15.8M | $25.8M | ||
| Q1 25 | $382.0K | $23.4M | ||
| Q4 24 | $378.0K | $26.3M | ||
| Q3 24 | $412.0K | $21.7M | ||
| Q2 24 | $415.0K | $20.2M | ||
| Q1 24 | $359.0K | $18.5M |
| Q4 25 | — | $-1.6M | ||
| Q3 25 | $5.6M | $-30.4M | ||
| Q2 25 | $5.7M | $-2.0M | ||
| Q1 25 | $5.2M | $-3.5M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $4.7M | $-2.9M | ||
| Q2 24 | $4.2M | $-3.5M | ||
| Q1 24 | $1.3M | $-1.8M |
| Q4 25 | — | 93.2% | ||
| Q3 25 | — | 92.9% | ||
| Q2 25 | — | 92.5% | ||
| Q1 25 | — | 92.2% | ||
| Q4 24 | — | 91.4% | ||
| Q3 24 | — | 90.8% | ||
| Q2 24 | — | 90.0% | ||
| Q1 24 | — | 89.8% |
| Q4 25 | 43.7% | 23.5% | ||
| Q3 25 | — | 11.2% | ||
| Q2 25 | 45.9% | -0.1% | ||
| Q1 25 | — | -8.9% | ||
| Q4 24 | — | 18.6% | ||
| Q3 24 | — | 3.6% | ||
| Q2 24 | — | -14.3% | ||
| Q1 24 | — | -8.3% |
| Q4 25 | — | -5.9% | ||
| Q3 25 | 1341.1% | -115.5% | ||
| Q2 25 | 36.0% | -7.8% | ||
| Q1 25 | 1352.1% | -15.1% | ||
| Q4 24 | — | -6.5% | ||
| Q3 24 | 1133.3% | -13.2% | ||
| Q2 24 | 1001.2% | -17.4% | ||
| Q1 24 | 373.3% | -9.5% |
| Q4 25 | $0.31 | $-0.32 | ||
| Q3 25 | $0.31 | $-3.40 | ||
| Q2 25 | $0.31 | $-0.23 | ||
| Q1 25 | $0.28 | $-0.41 | ||
| Q4 24 | $0.27 | $-0.18 | ||
| Q3 24 | $0.25 | $-0.34 | ||
| Q2 24 | $0.23 | $-0.41 | ||
| Q1 24 | $0.07 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $253.6M | $5.9M |
| Total Assets | $2.3B | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $16.6M | ||
| Q3 25 | — | $14.9M | ||
| Q2 25 | — | $17.0M | ||
| Q1 25 | — | $20.7M | ||
| Q4 24 | — | $15.9M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $6.2M | ||
| Q1 24 | — | $2.8M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $253.6M | $5.9M | ||
| Q3 25 | $249.8M | $6.1M | ||
| Q2 25 | $243.2M | $35.4M | ||
| Q1 25 | $242.3M | $36.7M | ||
| Q4 24 | $235.4M | $39.4M | ||
| Q3 24 | $230.8M | $39.8M | ||
| Q2 24 | $226.5M | $41.7M | ||
| Q1 24 | $220.7M | $43.3M |
| Q4 25 | $2.3B | $72.9M | ||
| Q3 25 | $2.3B | $71.1M | ||
| Q2 25 | $2.2B | $98.8M | ||
| Q1 25 | $2.2B | $96.4M | ||
| Q4 24 | $2.2B | $88.1M | ||
| Q3 24 | $2.3B | $88.5M | ||
| Q2 24 | $2.3B | $73.4M | ||
| Q1 24 | $2.2B | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $23.9M | $3.9M |
| Free Cash FlowOCF − Capex | $23.8M | $3.9M |
| FCF MarginFCF / Revenue | 140.7% | 14.0% |
| Capex IntensityCapex / Revenue | 0.3% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.0M | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.9M | $3.9M | ||
| Q3 25 | $7.6M | $2.2M | ||
| Q2 25 | $3.3M | $2.7M | ||
| Q1 25 | $5.4M | $-2.0M | ||
| Q4 24 | $18.2M | $932.0K | ||
| Q3 24 | $4.7M | $2.1M | ||
| Q2 24 | $1.6M | $-1.4M | ||
| Q1 24 | $7.2M | $-1.6M |
| Q4 25 | $23.8M | $3.9M | ||
| Q3 25 | $7.6M | $1.1M | ||
| Q2 25 | $3.3M | $902.7K | ||
| Q1 25 | $5.4M | $-3.7M | ||
| Q4 24 | $18.1M | $859.9K | ||
| Q3 24 | $4.6M | $2.0M | ||
| Q2 24 | $1.5M | $-1.5M | ||
| Q1 24 | $7.1M | $-1.7M |
| Q4 25 | 140.7% | 14.0% | ||
| Q3 25 | 1818.0% | 4.2% | ||
| Q2 25 | 20.8% | 3.5% | ||
| Q1 25 | 1413.6% | -15.9% | ||
| Q4 24 | 4786.0% | 3.3% | ||
| Q3 24 | 1121.8% | 9.4% | ||
| Q2 24 | 361.2% | -7.3% | ||
| Q1 24 | 1988.3% | -9.0% |
| Q4 25 | 0.3% | 0.3% | ||
| Q3 25 | 0.2% | 4.0% | ||
| Q2 25 | 0.1% | 6.8% | ||
| Q1 25 | 4.2% | 7.4% | ||
| Q4 24 | 37.3% | 0.3% | ||
| Q3 24 | 14.1% | 0.0% | ||
| Q2 24 | 12.8% | 0.3% | ||
| Q1 24 | 3.9% | 0.4% |
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVCB
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
